"Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s" was originally created and published ...

In July, Cognition Therapeutics reported that participants in the proof-of-concept Phase 2 ‘SHINE' study who were treated with CT1812 for six months showed a consistent trend in cognitive ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from LIGHTWAVE, a 12-week, Phase 2 randomized, double-blind, placebo-controlled ...